NCT07098351View on ClinicalTrials.gov

Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Adverse EventPeritoneal DialysisModerate-to-severe PruritusChronic Kidney Disease-associated Itch

Interventions

DRUG

Remitch

Nalfurafine 2.5μg daily for 2 weeks. Afterwards, the dose can be increased to 5μg daily if necessary (maximum dose not exceeding 5μg daily), continued for another 2 weeks.

Trial Locations (1)

510080

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors

lead

Guangdong Provincial People's Hospital

OTHER

NCT07098351 - Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis | Biotech Hunter | Biotech Hunter